Home  »  Trending   »  Daily High to Daily Low: Is It Safe to Buy Arbutus...

Daily High to Daily Low: Is It Safe to Buy Arbutus Biopharma Corporation (ABUS)?

Share on facebook
Share on twitter
Share on linkedin
Share on whatsapp

Arbutus Biopharma Corporation (NASDAQ:ABUS) went down by -4.55% from its latest closing price compared to the recent 1-year high of $6.50. The company’s stock price has collected -9.92% of loss in the last five trading sessions. Press Release reported on 01/04/22 that Arbutus to Participate at H.C. Wainwright Bioconnect Virtual Conference

Is It Worth Investing in Arbutus Biopharma Corporation (NASDAQ :ABUS) Right Now?

Plus, the 36-month beta value for ABUS is at 2.67. Opinions of the stock are interesting as 3 analysts out of 5 who provided ratings for Arbutus Biopharma Corporation declared the stock was a “buy,” while 0 rated the stock as “overweight,” 2 rated it as “hold,” and 0 as “sell.”


3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Sponsored


The average price from analysts is $6.30, which is $2.94 above the current price. ABUS currently public float of 93.64M and currently shorts hold a 8.61% ratio of that float. Today, the average trading volume of ABUS was 9.59M shares.

ABUS’s Market Performance

ABUS stocks went down by -9.92% for the week, with a monthly drop of -18.84% and a quarterly performance of -20.57%, while its annual performance rate touched -18.05%. The volatility ratio for the week stands at 5.87% while the volatility levels for the past 30 days are set at 7.05% for Arbutus Biopharma Corporation. The simple moving average for the period of the last 20 days is -14.70% for ABUS stocks with a simple moving average of -2.41% for the last 200 days.

Analysts’ Opinion of ABUS

Many brokerage firms have already submitted their reports for ABUS stocks, with Jefferies repeating the rating for ABUS by listing it as a “Hold.” The predicted price for ABUS in the upcoming period, according to Jefferies is $5 based on the research report published on February 25th of the previous year 2021.

H.C. Wainwright, on the other hand, stated in their research note that they expect to see ABUS reach a price target of $10. The rating they have provided for ABUS stocks is “Buy” according to the report published on December 17th, 2020.

JMP Securities gave a rating of “Mkt Outperform” to ABUS, setting the target price at $8 in the report published on July 27th of the previous year.

ABUS Trading at -10.73% from the 50-Day Moving Average

After a stumble in the market that brought ABUS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -48.31% of loss for the given period.

Volatility was left at 7.05%, however, over the last 30 days, the volatility rate increased by 5.87%, as shares sank -22.94% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -16.63% lower at present.

During the last 5 trading sessions, ABUS fell by -9.92%, which changed the moving average for the period of 200-days by +3.07% in comparison to the 20-day moving average, which settled at $3.89. In addition, Arbutus Biopharma Corporation saw -13.62% in overturn over a single year, with a tendency to cut further losses.

Insider Trading

Reports are indicating that there were more than several insider trading activities at ABUS starting from Sofia Michael J., who sale 200,000 shares at the price of $5.09 back on Dec 01. After this action, Sofia Michael J. now owns 1,303,403 shares of Arbutus Biopharma Corporation, valued at $1,018,000 using the latest closing price.

McElhaugh Michael J., the Chief Business Officer of Arbutus Biopharma Corporation, sale 20,000 shares at $5.00 during a trade that took place back on Feb 09, which means that McElhaugh Michael J. is holding 1,307,457 shares at $100,000 based on the most recent closing price.

Stock Fundamentals for ABUS

Equity return is now at value 201.80, with -59.30 for asset returns.

>> 7 Top Picks for the Post-Pandemic Economy <<

Leave a Comment

Your email address will not be published. Required fields are marked *

Is Teradyne Inc. (TER) a Keeper?

Teradyne Inc. (NASDAQ:TER) went up by 3.99% from its latest closing price compared to the recent 1-year high of $168.91. The company’s stock price has

Heading

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam